Research

Mixed

Combining different weight-lowering drugs with complementary mechanisms (e.g., GLP-1 RA with activin receptor antagonist) can enhance weight loss and preserve lean body mass, potentially offering superior cardiovascular protection compared to monotherapy.

For some patients, taking a single weight-loss drug might lead to muscle loss, which isn't ideal for heart health. New combination therapies, such as pairing a GLP-1 drug with a muscle-preserving agent, are being developed to prevent this. These combinations can lead to greater fat loss and better preservation of muscle mass, which is crucial for metabolic health. While these are still emerging, they represent a promising approach for those who struggle with muscle loss on standard treatments.

ModerateSupportsMEDIUM confidence
The combined use of different molecules could minimize their side effects, for instance, by minimizing muscle wasting observed during glucagon-like peptide 1 receptor agonists (GLP1-RAs) therapy... combination therapy with semaglutide and bimagrumab enhanced weight loss and led to a 10% increase in LBM, also improving exercise performance and circulating markers of adipose inflammation
Alessandro Ciarloni et al. · Biomedicines · 2026

Why this rating

Supported by preclinical data and ongoing Phase 2 trials, but long-term human data on MACE for combinations is lacking.

Source

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review

Alessandro Ciarloni et al. · Biomedicines · 2026

DOI 10.3390/biomedicines14040778

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →